Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 19/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 19/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 5/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | CCNH | P51946 | 1/20 | 0.70 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.69 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979763 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23924257 | 1.00 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL16171317 | 0.89 | MAPK8 (0.81) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23870567 | 0.87 | MAPK8 (0.78) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL14979771 | 0.87 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL18313157 | 0.83 | CDK7 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL22095472 | 0.83 | MAPK8 (0.87) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL22095474 | 0.83 | MAPK8 (0.87) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL29453371 | 0.83 | MAPK8 (0.87) | MAPK8MAPK9MAPK10CDK7CCNH | |
| SCHEMBL23924398 | 0.82 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | MAPK8 1803/4885MAPK9 2549/4885MAPK10 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.